These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17063513)

  • 21. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
    Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does transient HAART during primary HIV-1 infection lower the virological set-point?
    Desquilbet L; Goujard C; Rouzioux C; Sinet M; Deveau C; Chaix ML; Séréni D; Boufassa F; Delfraissy JF; Meyer L;
    AIDS; 2004 Dec; 18(18):2361-9. PubMed ID: 15622312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship of in vivo and ex vivo levels of TH1 and TH2 cytokines with viremia in HAART patients with and without opportunistic infections.
    Sindhu S; Toma E; Cordeiro P; Ahmad R; Morisset R; Menezes J
    J Med Virol; 2006 Apr; 78(4):431-9. PubMed ID: 16482539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma.
    Simonelli C; Zanussi S; Cinelli R; Dal Maso L; Di Gennaro G; D'Andrea M; Nasti G; Spina M; Vaccher E; De Paoli P; Tirelli U
    Clin Infect Dis; 2003 Sep; 37(6):820-7. PubMed ID: 12955644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome.
    Kitchen CM; Kitchen SG; Dubin JA; Gottlieb MS
    Clin Infect Dis; 2001 Aug; 33(4):466-72. PubMed ID: 11462181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome.
    García-Gascó P; Maida I; Blanco F; Barreiro P; Martín-Carbonero L; Vispo E; González-Lahoz J; Soriano V
    J Antimicrob Chemother; 2008 Mar; 61(3):699-704. PubMed ID: 18192682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discordant response to HAART: reduction of viremia and replicative capacity of HIV strains in patients after genotype guided change of therapy.
    Sarmati L; Montano M; Dori L; Buonomini AR; D'Ettorre G; Vullo V; Andreoni M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):95-8. PubMed ID: 15646070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy.
    Di Mascio M; Ribeiro RM; Markowitz M; Ho DD; Perelson AS
    Math Biosci; 2004; 188():47-62. PubMed ID: 14766093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early plasmacytoid dendritic cell changes predict plasma HIV load rebound during primary infection.
    Pacanowski J; Develioglu L; Kamga I; Sinet M; Desvarieux M; Girard PM; Hosmalin A
    J Infect Dis; 2004 Nov; 190(10):1889-92. PubMed ID: 15499547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
    Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F;
    HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
    Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
    Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
    Collazos J; Asensi V; Cartón JA
    AIDS; 2007 Apr; 21(7):835-43. PubMed ID: 17415038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First HAART in HIV-infected patients with high viral load: value of HIV RNA levels at 12 weeks to predict virologic outcome.
    Townsend D; Troya J; Maida I; Pérez-Saleme L; Satta G; Wilkin A; Barreiro P; Pegram PS; Soriano V; Mura MS; Núñez M
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(5):314-7. PubMed ID: 19759257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.
    Roux P; Carrieri MP; Cohen J; Ravaux I; Poizot-Martin I; Dellamonica P; Spire B
    Clin Infect Dis; 2009 Nov; 49(9):1433-40. PubMed ID: 19807275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiretroviral therapy in previously untreated adults infected with the human immunodeficiency virus type I: established and potential determinants of virological outcome.
    Lowe SH; Prins JM; Lange JM
    Neth J Med; 2004 Dec; 62(11):424-40. PubMed ID: 15685893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
    Chaix ML; Desquilbet L; Descamps D; Costagliola D; Deveau C; Galimand J; Goujard C; Signori-Schmuck A; Schneider V; Tamalet C; Pellegrin I; Wirden M; Masquelier B; Brun-Vezinet F; Rouzioux C; Meyer L; ;
    Antivir Ther; 2007; 12(8):1305-10. PubMed ID: 18240870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
    Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
    AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy.
    Brumme ZL; Brumme CJ; Chui C; Mo T; Wynhoven B; Woods CK; Henrick BM; Hogg RS; Montaner JS; Harrigan PR
    J Infect Dis; 2007 Jun; 195(11):1694-704. PubMed ID: 17471440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.